These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 31537486)

  • 21. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH.
    Wang H; Gu J; Liang X; Mao X; Wang Z; Huang W
    Semin Hematol; 2020 Jan; 57(1):26-30. PubMed ID: 32690141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
    Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
    Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic biomarkers for adult haemophagocytic lymphohistiocytosis in critically ill patients (HEMICU): a prospective observational study protocol.
    Lachmann G; Knaak C; von Haefen C; Paeschke N; Meisel C; Nyvlt P; Schuster FS; Piper SK; Kruppa J; Vorderwülbecke G; Balzer F; La Rosée P; Schenk T; Unterwalder N; Kölsch U; Lachmann N; Akyüz L; Brunkhorst FM; Volk HD; Keh D; Spies C
    BMJ Open; 2019 Oct; 9(10):e032695. PubMed ID: 31666276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
    Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
    Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
    Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
    Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han MK; Antila M; Ficker JH; Gordeev I; Guerreros A; Bernus AL; Roquilly A; Sifuentes-Osornio J; Tabak F; Teijeiro R; Bandelli L; Bonagura DS; Shu X; Felser JM; Knorr B; Cao W; Langmuir P; Lehmann T; Levine M; Savic S
    Lancet Rheumatol; 2022 May; 4(5):e351-e361. PubMed ID: 35368384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F
    Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
    Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
    Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does your unwell patient have haemophagocytic lymphohistiocytosis?
    Holloway A; Ahmed S; Manson JJ
    Br J Hosp Med (Lond); 2024 Mar; 85(3):1-12. PubMed ID: 38557089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
    Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
    Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.